Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of cenerimod in moderate to severe systemic lupus erythematosus
2018-001808-11Phase 2Completed
- Sponsor
- Idorsia
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cenerimod in systemic lupus erythematosus (SLE) (5 arms), sponsored by Idorsia. Primary endpoint: Change from baseline to Month 6 in mSLEDAI-2K score. Started Aug 2018; status: completed.
02
Drugs
cenerimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2018-001808-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001808-11.